Granules India Limited receives final approval from USFDA for its new drug
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...
Granules shares gain over 5% on U.S. FDA nod for ADHD generic capsules
Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.
Healthline16h
What You Need to Know About the Quantified Behavioral (Qb) Test
A QbTest is used during an assessment for ADHD. It helps doctors and mental health professionals determine whether someone ...
Granules India gets USFDA’s nod for ADHD generic
Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...
Daily Herald2h
Rise in diagnoses is prompting more US adults to ask: ‘Do I have ADHD?’
Allison Burk's teenage daughter struggled with uncontrolled emotions, a shrinking attention span and a growing tendency to ...
newsdrum22h
Granules India gets USFDA nod for attention deficit hyperactivity disorder treatment capsules
Pharmaceuticals firm, Granules India Ltd on Thursday said its arm has received a final nod from the US health regulator for its generic version of ...
VOCM News16h
ADHD Diagnosis Tied to Reduced Lifespan, Study Finds
Mortality data collected by researchers showed that life expectancy was reduced in diagnosed adults by close to 7 years in men and more than 8 years in women. The research paper released this month ...